Pfizer CEO: We can't pursue COVID-19 vaccine approval until late November

University of Maryland School of Medicine the first patient enrolled in Pfizer's COVID-19 coronavirus vaccine clinical trial at the University of Maryland School of Medicine in Baltimore receives an injecti

Vaccine roll out being considered for December, as sources say likelihood is '50/50'

Despite the global push for a Covid-19 vaccine, with dozens in clinical trials and hopes for initial inoculations this year, World Health Organization chief scientist Soumya Swaminathan reiterated that speedy, mass shots were unlikely, Reuters reported.

"WASHINGTON" The US pharmaceutical giant Pfizer expects to file for emergency use authorisation for its Covid-19 vaccine in late November, around two weeks after the Nov 3 US presidential election, it said on Friday.

"There will be a lot of guidance coming out, but I think an average person, a healthy young person might have to wait until 2022 to get a vaccine".

To understand the vaccine's efficacy-that is, whether it can protect individuals from COVID-19-a certain number of COVID-19 cases in the phase 3 trial need to be counted before investigators can compare the effectiveness of the vaccine with placebo.

Auckland commuters travelling during alert level 2.

In July, the U.S. Department of Health and Human Services and the Department of Defense (DoD) announced an agreement with Pfizer for an initial order of 100 million doses of a coronavirus vaccine for the price of $1.95 billion, following EUA or licensure.

Vaccine roll out being considered for December, as sources say likelihood is '50/50'
At Least One Effective COVID-19 Vaccine to Be Available by 2021, But Only in Limited Quantities, Says WHO

More than 150 countries have joined the WHO's Covax initiative, a cooperative arrangement in which nations combine forces to invest in vaccine development and agree to allocate the first doses based on population and then by level of risk.

Masked up people in Auckland's CBD.

The new rules also allow more healthcare workers to give COVID-19 and flu vaccines. State health leaders say the plan needs to be flexible so it can be adapted to work with the vaccine that makes it to the finish line first.

Dr. Soumya Swaminathan said Wednesday that she hoped a vaccine would be approved by 2021, but that it would likely be available in "limited quantities". But while the approach may have helped put Pfizer and Moderna in pole position in the vaccine race, a major drawback is they require deep-freezers for storage, which could limit distribution. The U.S. government is deciding who would be first in line, nearly certainly health care workers, and estimates there may be enough for widespread vaccinations in the spring.

"We are working at pace for the delivery of any potential COVID-19 vaccination programme as quickly as possible, but the scale of what is rolled out and when will depend on a safe, effective vaccine being available", he said. "The groups recommended to receive the vaccines could change in the future".

Bourla said Pfizer is "operating at the speed of science", but there are three steps that must happen before the company can release its COVID-19 vaccine.

Latest News